<DOC>
	<DOC>NCT00355901</DOC>
	<brief_summary>To assess the effects of visilizumab on the safety of subsequent salvage therapies in subjects who experienced disease progression in a previous visilizumab study and subsequently received salvage therapy.</brief_summary>
	<brief_title>An Observational Follow-up Study for Subjects Receiving Salvage Therapy After Previous Treatment in a Visilizumab Study for Intravenous Steroid-Refractory Ulcerative Colitis</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis, Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<criteria>Previous participation in a visilizumab study of IVSRUC. Disease progression while enrolled in a previous visilizumab study, and subsequent treatment with salvage therapy. Unable to understand the purpose and risks of the study, or unwilling or unable to provide a signed and dated informed consent. For U.S. sites, unwilling or unable to provide authorization to use protected health information.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2008</verification_date>
	<keyword>Ulcerative Colitis</keyword>
	<keyword>Colitis</keyword>
	<keyword>Steroid-Refractory</keyword>
	<keyword>Visilizumab</keyword>
	<keyword>Intravenous Steroid-Refractory Ulcerative Colitis (IVSR-UC)</keyword>
</DOC>